Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Symptom-Free Days More Likely With Fluticasone Furoate Therapy for Seasonal Allergic Rhinitis: Presented at EAACI By Sara Freeman LONDON -- June 11, 2010 -- Patients with seasonal allergic rhinitis (SAR) who are treated with fluticasone furoate (FF) are more likely to experience symptom-free days than if they receive other commonly used inhaled nasal steroids (INSs), according to research presented here at the 29th Congress of the European Academy of Allergy and Clinical Immunology (EAACI). Data from a cross-sectional study of 540 patients with SAR living in Germany, France, and Spain were reported by Beatrice Gueron, GSK, Respiratory Centre of Excellence, Montpelier, France, on June 7. "The objective of this study was to try to show a difference between different INSs in terms of quality of life and symptom-free days," said Gueron, noting that real-world data on the topic are lacking. The study, conducted in June 2009, involved 90 primary care physicians and 45 allergy specialists who were each asked to recruit 2 patients who had been treated with FF, 1 treated with mometasone furoate (MF), and 1 treated with fluticasone propionate (FP) for SAR for at least 2 weeks. Physicians completed forms relating to patient demographics, the Allergic Rhinitis and Its Impact on Asthma classification, frequency of visits, INS treatment, and coprescription. Patients provided information about the impact of SAR on their lifestyle, using the mini-Rhinoconjunctivitis Quality of Life Questionnaire (mini-RQLQ) used to assess overall well-being. The mean number of symptom-free days experienced by patients in the past 4 weeks was 15.38 for FF, 14.16 for MF, and 13.43 for FP. The 1.95-day difference between FF and FP was statistically significant (P = .046). Taking into account only patients who experience nasal and ocular symptoms, the response is greater. In this group of patients, the mean number of symptom-free days was 15.84 for FF, 13.50 for MF, and 12.94 for FP. The 2.34-day difference between FF and MF was statistically significant (P = .04), as was the 2.9-day difference between FF and FP (P = .01). FF-treated patients also had a better overall quality of life than those treated with MF or FP (mini-RQLQ = 1.43, 1.70, and 1.61, respectively). The difference in quality-of-life scores was only significant when comparing FF with MF (P = .026). "This study indicates that for SAR patients, treatment with FF is associated with more symptom-free days than with other INS treatments," Gueron concluded. Symptom-free days are particularly lower in patients who experience both nasal and ocular symptoms, she added, and quality of life with FF use is significantly improved compared with MF. Funding for this study was provided by GlaxoSmithKline. [Presentation title: Do Patients on Fluticasone Furoate (FF), Mometasone Furoate (MF) and Fluticasone Propionate (FP) Experience Similar Numbers of Symptom Free Days and Quality of Life in 3 European Countries. Abstract 380] E-mail this page to a friend or colleague! To print, use this version